Drug Makers

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

Its local production ramp-up remains unhurried as demand for boosters reduces

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Indian Health ministry sources say the Haryana-based drug maker is currently being probed for lapses in good manufacturing practices

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

British drugmaker Hikma to distribute Ryaltris while Glenmark will manufacture it

Drug maker Lupin on Thursday said it has inked a licensing pact with Japan-based I'rom Group Co for a product used in the treatment of postmenopausal women with osteoporosis, among others. Under the terms of the agreement, I'rom along with the Mumbai-based drugmaker will conduct clinical trials, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis. Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumours, among other indications. Following the completion of the clinical trial and receipt of marketing authorisation in Japan, I'rom will commercialise the product in the island nation, Lupin said in a statement. As part of the agreement, the drug maker will receive multiple milestone payments, it added. Currently, Denosumab is available under two brands, Pralia and Ranmark, with market size of about USD 500 mill

SII is working with Novavax to bring the Omicron-specific vaccine, as the nation continues to record a surge in the number of Covid-19 cases

A slew of drugmakers, including from US, France, Germany, Switzerland, and UK have halted exports of non-essential medicines to Russia, due to Ukraine war, while continuing supply of critical medicine

Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to deviation from standard manufacturing norms.

Competitive pricing among firms keeps rates at Rs 1,400-2,490 for full treatment

The health-care giant will split off its consumer division in 18 to 24 months, the company said in a statement

Drug maker Lupin on Thursday reported a consolidated net loss

With API supply, especially from China, facing some constraints because of lockdowns in several countries, demand from global clients had shot up for Indian players

Clocks 8.5% growth in December, up sharply from November's 1% due to revival in volume growth

Target company makes and supplies active pharmaeutical ingredients in the central nervous system space to some of the world's largest drug makers

The multiple talks confirm the bloc's more assertive stance on procuring potential Covid-19 shots and drugs after Washington's early moves in securing promising treatments and vaccines

Currently there are no specific regulations governing the sale of OTC products and this impacts both patient safety and access, says OPPI

IPA says it is bringing industry and regulators together to address these concerns

Action is taken when firms are found selling products at a price which is 10% higher than the MRP